PL339368A1 - Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b - Google Patents

Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b

Info

Publication number
PL339368A1
PL339368A1 PL98339368A PL33936898A PL339368A1 PL 339368 A1 PL339368 A1 PL 339368A1 PL 98339368 A PL98339368 A PL 98339368A PL 33936898 A PL33936898 A PL 33936898A PL 339368 A1 PL339368 A1 PL 339368A1
Authority
PL
Poland
Prior art keywords
pct
combination
alkyl
monoamine oxidase
partial agonist
Prior art date
Application number
PL98339368A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL339368A1 publication Critical patent/PL339368A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL98339368A 1997-09-18 1998-09-09 Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b PL339368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001602 WO1999013878A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
PL339368A1 true PL339368A1 (en) 2000-12-18

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98339368A PL339368A1 (en) 1997-09-18 1998-09-09 Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b

Country Status (27)

Country Link
US (1) US6159970A (enExample)
EP (1) EP1014986B1 (enExample)
JP (1) JP2001516719A (enExample)
KR (2) KR20010024087A (enExample)
CN (1) CN1278727A (enExample)
AR (1) AR013503A1 (enExample)
AT (1) ATE270889T1 (enExample)
AU (1) AU752719B2 (enExample)
BR (1) BR9812236A (enExample)
CA (1) CA2302204A1 (enExample)
DE (1) DE69825062T2 (enExample)
DK (1) DK1014986T3 (enExample)
EE (1) EE200000146A (enExample)
ES (1) ES2222603T3 (enExample)
HU (1) HUP0100621A2 (enExample)
ID (1) ID25789A (enExample)
IL (1) IL134775A0 (enExample)
IS (1) IS5401A (enExample)
MX (1) MXPA00002616A (enExample)
NO (1) NO20001400L (enExample)
PL (1) PL339368A1 (enExample)
PT (1) PT1014986E (enExample)
SE (1) SE9703376D0 (enExample)
SK (1) SK2832000A3 (enExample)
TR (1) TR200000725T2 (enExample)
WO (1) WO1999013878A1 (enExample)
ZA (1) ZA987804B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20090054453A1 (en) * 2006-03-17 2009-02-26 Lilian Alcaraz Novel Tetralins as 5-HT6 Modulators
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
EP4633638A1 (en) * 2022-12-14 2025-10-22 Luminous Mind Inc. Treatment of psychological factors affecting other medical conditions (pfaomc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
US6159970A (en) 2000-12-12
DE69825062D1 (de) 2004-08-19
SK2832000A3 (en) 2000-09-12
CA2302204A1 (en) 1999-03-25
NO20001400L (no) 2000-05-05
NO20001400D0 (no) 2000-03-17
SE9703376D0 (sv) 1997-09-18
ZA987804B (en) 1999-03-18
HUP0100621A2 (hu) 2001-08-28
ES2222603T3 (es) 2005-02-01
AU752719B2 (en) 2002-09-26
EP1014986A1 (en) 2000-07-05
JP2001516719A (ja) 2001-10-02
MXPA00002616A (es) 2002-04-24
DK1014986T3 (da) 2004-10-25
IS5401A (is) 2000-03-14
EE200000146A (et) 2001-02-15
CN1278727A (zh) 2001-01-03
ID25789A (id) 2000-11-02
ATE270889T1 (de) 2004-07-15
AR013503A1 (es) 2000-12-27
PT1014986E (pt) 2004-10-29
EP1014986B1 (en) 2004-07-14
KR20010024084A (ko) 2001-03-26
BR9812236A (pt) 2000-07-18
KR20010024087A (ko) 2001-03-26
IL134775A0 (en) 2001-04-30
TR200000725T2 (tr) 2000-08-21
DE69825062T2 (de) 2005-08-25
AU9193198A (en) 1999-04-05
WO1999013878A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
PL339368A1 (en) Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b
SE9703375D0 (sv) A new combination
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
GB9524157D0 (en) Therapeutic agents
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
SE0104332D0 (sv) Therapeutic agents
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DK0583485T3 (da) Ethanolaminderivater med sympathomimetiske og anti-pollakisuria-virkninger
NO943803L (no) Acylaminoindolderivater som 5-HT 1 agonister
ZA955105B (en) Thiazolidine derivatives their preparation and compositions containing them
IL108969A0 (en) Substituted (arylalkoxybenzyl) aminopropionamide derivatives, their preparation and pharmaceutical compositions containing them
NO308654B1 (no) Amid-derivater, fremgangsmÕter og mellomprodukter for fremstilling derav, deres anvendelse og farmasøytiske blandinger som inneholdende dem
FI943931A0 (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
IL127177A (en) ANTIPYSYCHOTIC 5-(1, 3, 4, 4a, 5, 9b-HEXAHYDRO-PYRIDO (3, 4-b) INDOL-2-YLALKYL) PYRIMIDIN-4-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK0706517T3 (da) Pyridazinonderivater med farmaceutisk virkning
SE9703374D0 (sv) A new combination
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
SE9804126D0 (sv) New pharmaceutical composition
SE9702534D0 (sv) Compounds
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf
DK1010694T3 (da) Spiroimidazolinderivater og deres anvendelse som alfa2-adrenerge antagonister og monoamin-genoptagningsblokkere
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler